Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, announced that The Lancet has published positive results from a pivotal Phase 3 trial evaluating zoliflodacin, its investigational single-dose oral antibiotic for treating uncomplicated urogenital gonorrhea. The trial was conducted in collaboration with the not-for-profit Global Antibiotic Research & Development Partnership. Dr. Edward Hook, Emeritus Professor of Medicine at the University of Alabama at Birmingham and protocol chair for the study, emphasized the ongoing public health challenge posed by gonorrhea and the rising threat of antimicrobial resistance. He noted that these findings offer compelling evidence that zoliflodacin could serve as an effective, convenient single-dose oral therapy, representing a significant advancement in the treatment of this infection.
Health Technology Insights: Astrin Biosciences Forms SAB to Boost AI Cancer Detection
Gonorrhea affects over 82 million people worldwide each year and can lead to severe long-term health consequences if untreated. The increasing prevalence of drug-resistant strains has made antimicrobial resistance a critical global health threat, as recognized by the World Health Organization. Neisseria gonorrhoeae has developed resistance to nearly all antibiotics previously used, including cephalosporins like ceftriaxone, which is currently the only recommended first-line therapy for uncomplicated infections.
Health Technology Insights: Mirum Pharma to Acquire Bluejay Therapeutics for Rare Disease
Stephanie Taylor, MD, Professor of Medicine and Medical Director of the LSU STD Research Laboratory, explained that the Phase 3 study demonstrated that zoliflodacin was non-inferior to a potent dual therapy of ceftriaxone and azithromycin. Microbiological cure rates at extragenital sites such as the pharynx and rectum were comparable between treatments, and both regimens showed similar safety profiles. The trial met pre-specified criteria for non-inferiority with a difference of 5.31 percent, and no serious adverse events were reported, while common side effects were mild and manageable.
The U.S. FDA has granted zoliflodacin Qualified Infectious Disease Product designation, enabling priority review and extended market exclusivity. Innoviva Specialty Therapeutics received FDA confirmation in June 2025 that the company’s New Drug Application has been accepted, with a target action date of December 15, 2025 under the Prescription Drug User Fee Act.
Dr. Patrik Hornak, Associate Program Director of the Infectious Disease Fellowship Program and Clinical Director of the AIDS Education & Training Center at the University of Texas Medical Branch, highlighted the urgent need for new treatment options. He noted that clinicians currently rely on a single first-line therapy for uncomplicated gonorrhea, and zoliflodacin offers the potential for a simple, effective oral alternative that could enable early intervention and better protect high-risk communities.
The Phase 3 trial was a multinational, randomized, controlled, open-label study designed to test non-inferiority against ceftriaxone plus azithromycin. The trial enrolled 930 adolescents and adults across 16 sites in Belgium, the Netherlands, South Africa, Thailand, and the U.S., regions with high gonorrhea prevalence. The study compared a single 3-gram oral dose of zoliflodacin with a single 500-milligram intramuscular injection of ceftriaxone plus 1 gram oral azithromycin, marking the largest clinical trial ever conducted for a new gonorrhea treatment. Funding and support came from multiple governments and organizations including Germany, the United Kingdom, Japan, the Netherlands, Switzerland, Luxembourg, Geneva, the South African Medical Research Council, and the Leo Model Foundation.
Zoliflodacin belongs to a new class of antibiotics known as spiropyrimidinetriones and works by inhibiting bacterial DNA gyrase, a critical enzyme for bacterial survival. Its mechanism is distinct from existing treatments and it has shown activity against strains resistant to current first-line therapies.
The Global Antibiotic Research & Development Partnership is a not-for-profit organization dedicated to combating antimicrobial resistance by developing and providing access to new antibiotic treatments. GARDP’s work is supported by governments, philanthropic organizations, and global health initiatives, including the Gates Foundation, Wellcome, EDCTP3, GSK, and other partners. This collaboration has been instrumental in advancing the development and clinical testing of zoliflodacin as a safe, effective, and accessible therapy for patients worldwide.
Health Technology Insights: Reid Waldman Wins Entrepreneur of the Year in Life Sciences
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
